Harmony Biosciences is trading 6.09% up at $41.98 in pre-market on October 2, versus the October 1 close of $39.57, after Deutsche Bank raised its price target to $42 from $39 and maintained a Hold rating.
- Deutsche Bank cited increased confidence in the company’s legal strategy to preserve Wakix exclusivity through 2030, raising its probability-of-success estimate to 80% from 70%.
- Harmony Biosciences announced a poster presentation on its ongoing Phase 3 HBS-301 trials at European Narcolepsy Days, scheduled for October 2–3.